Liu Y.,Guangxi Medical University |
He J.,Guangxi Orthopaedic Traumatology Hospital |
Chen X.,Guangxi Medical University |
Li J.,Guangxi Medical University |
And 4 more authors.
Cellular Physiology and Biochemistry | Year: 2014
Background: Previous studies have shown that some phytoestrogens inhibits proliferation and induces apoptosis in estrogen-dependent cancers via estrogen receptor (ER)-mediated signaling pathway. In view of the expression of ER in human osteosarcoma cells, the purpose of this study is to investigate whether formononetin and calycosin, two of the major isoflavones in Radix astragali, could also elicit anti-tumor activity against osteosarcoma, along with the underlying mechanism. Methods: Human osteosarcoma cells U2OS were respectively treated with various concentrations of formononetin or calycosin. Cell proliferation was determined by MTT assay, while apoptosis by flow cytometry. Next, the expression levels of apoptosis-related genes ERK, Akt, Bcl-2, Bax and caspase-3 were quantified by real-time PCR and Western blotting. Results: Formononetin exhibited higher anti-proliferative activities toward human osteosarcoma cells U2OS, when compared with calycosin. Therefore, U2OS cells were then respectively treated with various concentrations of formononetin, in order to elucidate the isoflavones-related signaling pathway. It was found that formononetin dose-dependently triggered apoptosis of U2OS cells in vitro. Furthermore, treatment of formononetin led to significant inactivation of ERK and Akt, followed by downregulation of Bcl-2, upregulation of Bax and finally increased expression of caspase-3. Conclusion: Formononetin is more effective than calycosin at promoting cell death of U2OS cells by induction of apoptosis, which is mediated by inactivation of ERK and Akt signaling pathways. Thus isoflavones, especially formononetin, may be useful as anti-cancer drugs for osteosarcoma through their apoptosis-inducing effects. © 2014 S. Karger AG, Basel.
Yang Y.,Guangxi Orthopaedic Traumatology Hospital |
Li X.-F.,Guangxi Orthopaedic Traumatology Hospital |
Luo D.-M.,Guangxi University |
Wen C.-H.,Guangxi University
Chinese Journal of Tissue Engineering Research | Year: 2013
BACKGROUND: Drynaria can promote bone growth and has made good clinical curative effect. Can the main ingredients of Naringin induce bone marrow measenchymal stem cells to differentiation into osteoblasts? OBJECTIVE: Through the use of Naringin to induce osteogenic differentiation of rabbit bone marrow mesenchymal stem cells, to observe the osteogenic ability of Naringin-induced rabbit bone marrow mesenchymal stem cells. METHODS: Adherence screening method was used to separate and culture the rabbit bone marrow mesenchymal stem cells. The well-grown third generation of bone marrow measenchymal stem cells were induced with 50 ug/L Naringin and classic osteogenic inducer respectively to differentiate into the osteoblasts, and the osteogenesis identification was performed. RESULTS AND CONCLUTION: Both the classic osteogenic inducer and Naringin induced liquid could induce the bone marrow mesenchymal stem cells to differentiation into osteoblasts with increasing matrix secretion and calcium nodules formation. The enzyme-linked immunosorbent assay showed that there was no significant difference in absorbance value of the cells between the Naringin induction group and the classic osteogenic inducer group. There was no significant difference in absorbance value of the cells induced with Naringin induced liquid and L-DMEN culture medium (P > 0.05). The results indicate that Naringin can induce the bone marrow mesenchymal stem cells to differentiate into osteoblasts without obvious toxic effect.